Evaluation of Possible Effects on the QTc Interval of CHF 4226 pMDI in Healthy Volunteers
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of single doses of therapeutic and
supratherapeutic doses of inhaled CHF 4226 pMDI on ventricular repolarization in healthy
subjects compared with placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Collaborator:
Chiesi Pharmaceuticals Inc.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination